ExThera’s proprietary Seraph 100 Microbind Affinity Blood Filter (Seraph 100) is the first CE-certified technology designed to reduce blood-borne pathogens during bloodstream infections. The device has been validated in pre-clinical studies and clinical trials in Europe, showing promise in solving the major unmet need for an immediate treatment prior to pathogen identification and antibiotic susceptibility testing.
Seraph’s broad-spectrum binding can significantly reduce the concentration of pathogens without damaging the blood, which makes it have extensive potential for clinical applications.
The company has evaluated the therapeutic use of Seraph 100 in extracorporeal circuits for the treatment of patients with drug-resistant and drug-susceptible pathogens during bloodstream infections.